[pubmed] Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neu
Posté : 28 mai 2021 12:00
J Cent Nerv Syst Dis. 2021 May 17;13:11795735211016080. doi: 10.1177/11795735211016080. eCollection 2021.
ABSTRACT
BACKGROUND: Rituximab is reserved for treating refractory myasthenia gravis (MG) patients. Here we report our experience with rituximab in AChR antibody positive generalized MG (gMG) and impending myasthenic crisis (IMC).
METHODS: This retrospective, observational study, conducted at a tertiary care, neuroimmunology clinic, analyzed the data of patients with AChR antibody positive gMG, treated with rituximab between 1st January 2016 and 30th October 2018.
RESULTS: Eleven patients with AChR antibody positive gMG received rituximab. Mean age of the cohort was 50.54 ± 18.71 years with 9 males. Seven out of 11 patients received rituximab in the early stage (
Source: https://pubmed.ncbi.nlm.nih.gov/3404591 ... 8&v=2.14.4